Armen Garo H: insider trades.
Armen Garo H reported 8 non-derivative transactions on 9 SEC ownership filings in Q3 2026: 7 open-market purchases ($31K) and 0 sales, across 2 companies.
- Transactions
- 8
- Purchases (P)
- 7
- Sales (S)
- 0
- Companies
- 2
- Name as filed
- ARMEN GARO H
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Protagenic Therapeutics, Inc. ew (PTIX) | Director, Officer · EXEC. CHAIR & PRINCIPAL OFF | 7 |
| Agenus Inc | Director, Officer · See Remarks | 1 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-21 | Protagenic Therapeutics, Inc. ew | P | 20,000 | $0.65 | 73,533 | Form 4 |
| 2026-08-20 | Protagenic Therapeutics, Inc. ew | P | 16,634 | $0.59 | 53,533 | Form 4 |
| 2026-08-19 | Protagenic Therapeutics, Inc. ew | P | 2,700 | $0.35 | 36,899 | Form 4 |
| 2026-08-11 | Protagenic Therapeutics, Inc. ew | P | 2,220 | $0.32 | 34,199 | Form 4 |
| 2026-08-06 | Protagenic Therapeutics, Inc. ew | P | 685 | $0.22 | 31,979 | Form 4 |
| 2026-08-05 | Protagenic Therapeutics, Inc. ew | P | 5,000 | $0.26 | 31,294 | Form 4 |
| 2026-07-30 | Protagenic Therapeutics, Inc. ew | P | 26,291 | $0.18 | 26,291 | Form 4 |
| 2026-07-10 | Agenus Inc | A | 4,852 | $3.35 | 371,108 | Form 4 |
Questions
What stock did Armen Garo H buy or sell?
Armen Garo H reported 8 non-derivative transactions on 9 SEC ownership filings in Q3 2026: 7 open-market purchases ($31K) and 0 sales, across 2 companies.
Is Armen Garo H the same person as other filers with this name?
This page covers SEC CIK 935679 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/armen-garo-h-935679.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.